For instance, the identification of specific biomarkers associated with tamoxifen resistance, such as SOX2 and AGR2, can guide the selection of alternative therapies for estrogen receptor-positive (ER+) breast cancer patients who exhibit resistance to standard treatments [114]. Here, ESR1 is linked to breast carcinoma.